December 19, 2016
Janssen asks FDA’s permission to treat adolescent plaque psoriasis patients with Solara
Janssen Biotech is looking to expand the usage of its prescription drug Stelara, as it has asked the U.S. Food…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 16, 2016
Lilly/Incyte’s rheumatoid arthritis drug gets CHMP’s recommendation for EMA’s approval
Eli Lilly and Incyte Corporation have gotten positive opinion from European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
December 16, 2016
Mylan Launches generic for EpiPen adrenaline injection, fights rising US drug prices
Mylan is launching its generic for EpiPen adrenaline injection at a wholesale acquisition cost (WAC) of $300 per epinephrine injection. As…
December 16, 2016
Novartis’s epilepsy drug gets CHMP’s positive opinion
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for…
December 16, 2016
ABIVAX welcomes Didier Blondel as CFO
ABIVAX has appointed Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.
December 16, 2016
FDA OK’s Cerenis’s CER-209 clinical trial for liver disease treatment
U.S. Food and Drug Administration (FDA) has given green light to Cerenis Therapeutics to proceed with CER-209 clinical trial.
December 16, 2016
Novartis buys Ziarco Group
Novartis has entered into a definitive agreement to buy a privately held company Ziarco Group Limited, focused on producing dermatology…
December 16, 2016
RAC Approves Cellectis’s UCART123 Phase 1 study protocols in AML and BPDCN
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
December 16, 2016
MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
MDxHealth’s laboratory in Nijmegen, The Netherlands has received ISO 13485:2016 certification for the design, development, manufacture and distribution of in…
December 16, 2016
Allergan’s subsidiaries Forest to pay $38M for bad marketing practices
Allergan’s indirect subsidiaries Forest Laboratories, LLS and Forest Pharmaceuticals, Inc. are about to pay $38 million for bad sales and…